Klaritromicin Krka

Clarithromycin, the active ingredient in Klaritromicin Krka, is a macrolide antibiotic presented as an oral tablet for systemic use. It treats a range of bacterial infections, including respiratory and skin infections, and is used in combination regimens for Helicobacter pylori eradication.

GNH USA supplies Klaritromicin Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clarithromycin is employed to treat bacterial infections affecting the respiratory tract, sinuses, skin and gastrointestinal system.

- Community‑acquired pneumonia: eradicates susceptible pathogens, improving breathing and preventing complications. - Acute bacterial sinusitis: relieves sinus inflammation by eliminating the causative bacteria. - Acute bacterial bronchitis: reduces cough and bacterial load in the lower airways. - Skin and soft‑tissue infections: clears susceptible skin pathogens and promotes healing. - Helicobacter pylori eradication: part of combination therapy to eliminate H. pylori and heal gastric ulcers.

Clarithromycin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: transient upset stomach. - Diarrhea: loose stools, often mild. - Abdominal pain: cramping or discomfort. - Altered taste: metallic or bitter sensation. - Headache: mild to moderate. - Vomiting: occasional episodes.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis): rash, swelling, difficulty breathing. - QT interval prolongation: risk of cardiac arrhythmias. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Clostridioides difficile‑associated diarrhea: severe colitis. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: extensive skin blistering. - Cardiac arrhythmias: irregular heartbeats beyond QT prolongation.

When prescribing clarithromycin, clinicians should consider several safety measures.

- Assess renal and hepatic function: dose adjustment may be required in impairment. - Avoid use in patients with known macrolide hypersensitivity: discontinue if reaction occurs. - Monitor ECG in patients with cardiac risk factors: risk of QT prolongation. - Use caution in pregnancy: limited data, weigh benefits against potential risks. - Avoid concomitant use with other QT‑prolonging agents: increased cardiac risk. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Clarithromycin interacts with several medicines; some require avoidance, others close monitoring.

Major Interactions (Avoid): - Erythromycin or other macrolides: additive toxicity and increased risk of QT prolongation. - Cisapride or domperidone: heightened risk of serious cardiac events. - HIV protease inhibitors (e.g., ritonavir): markedly increased clarithromycin plasma levels. - Theophylline: elevated theophylline concentrations leading to toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: enhanced anticoagulant effect, monitor INR. - Statins such as simvastatin or lovastatin: increased risk of myopathy. - Carbamazepine: reduced clarithromycin exposure, may diminish efficacy. - Digoxin: modest increase in serum levels, monitor for toxicity.